Zilovertamab is a monoclonal antibody commercialized by Oncternal Therapeutics, with a leading Phase II program in Marginal Zone B-cell Lymphoma. According to Globaldata, it is involved in 8 clinical trials, of which 3 were completed, and 5 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Zilovertamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Zilovertamab is expected to reach an annual total of $28 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zilovertamab (UC-961) is under development for the treatment of relapsed or refractory chronic lymphocytic leukemia, marginal zone b-cell lymphoma, metastatic castration resistant prostate cancer, relapsed or refractory diffuse large B-cell lymphoma, metastatic or locally advanced unresectable triple negative breast cancer, HER2 negative breast cancer and mantle cell leukemia. The therapeutic candidate is administered intravenously and it acts by targeting ROR1. It was under development for ovarian cancer.
Oncternal Therapeutics Overview
Oncternal Therapeutics (Oncternal), formerly GTx, is a biopharmaceutical company that discovers, develops, and commercializes novel targeted hormonal therapies. It develops small molecules that target hormone pathways for the treatment of various cancers, including breast and prostate cancer and other serious medical conditions. The company’s pipeline program includes cirmtuzumab, a humanized monoclonal antibody for the treatment of chronic lymphocytic leukemia, metastatic breast cancer and and mantle cell lymphoma; TK216 for treatment of Ewing sarcoma, prostate cancer and acute myeloid lukemia and a ROR1-targeted CAR-T therapy candidate for treatment hematologic and solid tumors. It conducts preclinical development activities in the US and Europe. Oncternal is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$4.3 million for the fiscal year ended December 2021 (FY2021), an increase of 27.9% over FY2020. The operating loss of the company was US$31.4 million in FY2021, compared to an operating loss of US$17.5 million in FY2020. The net loss of the company was US$31.3 million in FY2021, compared to a net loss of US$17.2 million in FY2020. The company reported revenues of US$0.4 million for the third quarter ended September 2022, an increase of 100% over the previous quarter.
For a complete picture of Zilovertamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.